[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524139":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":26,"locations":35,"responsibleParty":63,"collaborators":11,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":11,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"NEXTGEN Bioscience","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NXC736","EXPERIMENTAL",null,[13],"Drug: NXC736",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","oral administration",[9],{"type":21,"name":15,"description":22,"armGroupLabels":25,"otherNames":11},[15],[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Heesun Kim","CONTACT","82-31-606-3220","flower@nextgenbio.co.kr",{"name":33,"role":29,"phone":11,"phoneExt":11,"email":34},"YangHye Park","yhpark@nextgenbio.co.kr",[36,53],{"facility":37,"status":38,"city":39,"state":11,"zip":40,"country":41,"countryCode":11,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Seoul National University Hospital.","RECRUITING","Seoul","03080","South Korea",{"type":43,"coordinates":44},"Point",[45,46],126.9784,37.566,{"lat":46,"lon":45},[49],{"name":50,"role":29,"phone":51,"phoneExt":11,"email":52},"Osang Kwon","82-1800-1252","oskwon@snu.ac.kr",{"facility":54,"status":38,"city":39,"state":11,"zip":55,"country":41,"countryCode":11,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"Kyung Hee University Hospital at Gangdong","05278",{"type":43,"coordinates":57},[45,46],{"lat":46,"lon":45},[60],{"name":61,"role":29,"phone":51,"phoneExt":11,"email":62},"Bark-Lynn Lew","bellotte@hanmail.net",{"type":64,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100524139","phase-2-safety-and-efficacy-of-oral-nxc-736-in-adult-participants-with-moderate-and-severe-alopecia-areata-100524139",false,"NCT06104839","Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata","Inclusion Criteria:\n\n* Men or women between ≥19 and ≤65 years of age at the time of informed consent\n* Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \\\u003C 95% at Screening and Day 1\u002FBaseline\n* Current episode of hair loss for ≥6 months but \\\u003C8 years\n* Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator\n* Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study\n\nExclusion Criteria:\n\n* Participants with the following medical history confirmed during screening:\n\n  * ohter Types of alopecia other than alopecia areata (such as cicatricial\u002Fscarring alopecia \\[including central centrifugal cicatricial alopecia\\], traction alopecia, androgenic alopecia, telogen effluvium, etc.)\n* Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment\n* Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors","ALL","19 Years","65 Years",{"count":76,"type":77},73,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).",[83],"Alopecia Areata","2026-04-09",{"date":86,"type":87},"2026-04-13","ACTUAL",{"date":89,"type":87},"2024-09-01",{"date":91,"type":77},"2027-01-31",{"name":5,"class":6},2]